Asthma and COPD Section
-
The emerging role of biologic therapy in asthma-COPD overlap
Biologics such as dupilumab, mepolizumab, benralizumab, and tezepelumab are an emerging option for select patients with asthma-COPD overlap, particularly those with T2-high inflammatory phenotypes.
-
Expanding treatments for COPD management
Recent FDA approval of dupilumab and ensifentrine marks significant progress in therapies targeting inflammation, lung function, and symptom relief for patients with COPD.
-
Expanding recommendations for RSV vaccination
Respiratory syncytial virus (RSV) has been increasingly recognized as a prevalent cause of lower respiratory tract infection (LRTI) among adults in the United States. The risk of hospitalization and mortality […]
-
Emerging role of biologics in COPD: A new direction
Remodeling of airways and destruction of parenchyma by immune and inflammatory mechanisms are the leading cause of lung function decline in patients with COPD. Type 2 inflammation has been recognized […]
